CD226 and Miyoshi myopathy: In this regard, our laboratory has recently characterized the capability of IMiDs to upregulate cell surface expression of the NKG2D and DNAM-1 NK cell-activating ligands MICA and PVR/CD155 on MM cells, thus enhancing NK cell recognition and killing.